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ARTICLES

Bone Marrow Failure

In vivo effects of horse and rabbit antithymocyte globulin in patients with
severe aplastic anemia
Xingmin Feng,1 Phillip Scheinberg,1 Angelique Biancotto,2 Olga Rios,1 Sarah Donaldson,3 Colin Wu,4 Haiyun Zheng,5
Kazuya Sato,1 Danielle M. Townsley,1 J. Philip McCoy,2,6 and Neal S. Young1

1
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Medicine, St. Louis, MO; 4Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health,
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ABSTRACT

We recently reported that rabbit antithymocyte globulin was markedly inferior to horse antithymocyte globulin as a
primary treatment for severe aplastic anemia. Here we expand on our findings in this unique cohort of patients.
Rabbit antithymocyte globulin was detectable in plasma for longer periods than horse antithymocyte globulin; rabbit
antithymocyte globulin in plasma retained functional capacity to bind to lymphocytes for up to 1 month, horse
antithymocyte globulin for only about 2 weeks. In the first week after treatment there were much lower numbers of
neutrophils in patients treated with rabbit antithymocyte globulin than in patients receiving horse antithymocyte
globulin. Both antithymocyte globulins induced a “cytokine storm” in the first 2 days after administration. Compared
with horse antithymocyte globulin, rabbit antithymocyte globulin was associated with higher levels of chemokine
(C-C motif) ligand 4 during the first 3 weeks. Besides a much lower absolute number and a lower relative frequency
of CD4+ T cells, rabbit antithymocyte globulin induced higher frequencies of CD4+CD38+, CD3+CD4-CD8- T cells,
and B cells than did horse antithymocyte globulin. Serum sickness occurred around 2 weeks after infusion of both
types of antithymocyte globulin. Human anti-antithymocyte globulin antibodies, especially of the IgM subtype, correlated with serum sickness, which appeared concurrently with clearance of antithymocyte globulin in blood and
with the production of cytokines. In conclusion, rabbit and horse antithymocyte globulins have very different pharmacokinetics and effects on neutrophils, lymphocyte subsets, and cytokine release. These differences may be related
to their efficacy in suppressing the immune system and restoring hematopoiesis in bone marrow failure.
Clinicaltrials.gov identifier: NCT00260689.

Introduction
Severe acquired aplastic anemia (AA) is a life-threatening
disease, characterized by pancytopenia and bone marrow
hypocellularity.1 T-cell-mediated destruction of hematopoietic progenitors and stem cells is pathogenic in most cases.
Overall, 60-70% of AA patients achieve a hematologic
response to a single course of immunosuppressive therapy.2,3
The most effective regimen is horse antithymocyte globulin
(hATG) in combination with cyclosporine A; this combination is superior to either ATG or cyclosporine alone.4,5 ATG is
a heterologous anti-serum derived from animals immunized
with human lymphocytes. There are various ATG preparations, which differ in the source of human T cells used as antigens (thymocytes, peripheral lymphocytes or T-cell lines)
and/or the inoculated animals (horse, rabbit, or pig). Most
large clinical trials have tested hATG, which has been considered the standard for AA treatment. However, one hATG
preparation (Lymphoglobulin) was withdrawn from
European and Asian markets in 2007, and rabbit ATG (rATG)
became the sole ATG available outside the USA. At the time,
this substitution was not predicted to be problematic, since

different ATG formulations were assumed to work equally
well in AA.
To evaluate the equivalence of hATG and rATG, we first
performed a prospective, randomized study to compare these
two formulations in treatment-naïve patients with severe AA.
Surprisingly, in our patient population rATG/cyclosporine A
was markedly inferior to hATG/cyclosporine A as first therapy in severe AA: the rate of hematologic response at 6
months was much in favor of hATG (68%) as compared with
rATG (37%). The 3-year survival rate was also better in the
hATG group than in the rATG group (96% versus 76%).6
Some in vitro studies of differences between hATG and
rATG formulations have been reported previously, but the
scope of such studies was limited and the relevance of the
observations in humans remains unclear.7,8 In view of the
marked differences in the clinical outcomes in our randomized clinical study, we here expand on our findings in this
unique cohort of patients, in order to understand mechanistic
differences underlying the effects of these two biologics. As
serum sickness (SS) is a complication of animal anti-serum
infusion, we also investigated immunological changes associated with this syndrome in ATG-treated patients.
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Methods
Severe aplastic anemia: patients and treatment
Consecutive patients, all older than 2 years of age and with a
diagnosis of severe AA, were enrolled from December 2005
through July 2010 at the Mark O. Hatfield Clinical Research
Center of the National Institutes of Health, in Bethesda (Maryland,
USA). Patients (or their legal guardians) provided written informed
consent according to a protocol approved by the institutional
review board of the National Heart, Lung, and Blood Institute.
Sixty rATG-treated and 60 hATG-treated patients with severe AA
were included in the study. There were no significant differences
in demographic or clinical characteristics between the two groups;
details have already been reported.6 rATG (Thymoglobulin;
Genzyme, Cambridge, MA, USA) was administered intravenously at a dose of 3.5 mg/kg/day for 5 days and hATG (ATGAM,
Upjohn, Kalamazoo, MI, USA) was given at a dose of 40
mg/kg/day for 4 days. Cyclosporine A accompanied both rATG
and hATG therapy, and the dose was adjusted to maintain a blood
concentration between 200 and 400 ng/mL.

Sample collection and preparation
Blood samples were obtained at baseline prior to treatment,
weekly in the first month, and at 3 and 6 months after ATG treatment. Plasma was obtained by centrifuging peripheral blood samples and stored in aliquots at -80°C until analysis.
Twenty-seven cytokines in the plasma were measured simultaneously by magnetic multiplex assays (Luminex). ATG concentrations and titers of human anti-ATG antibodies were detected by
enzyme-linked immunosorbent assay (ELISA). Reconstitution of
immune cells was evaluated by flow cytometry as described previously.6 Details regarding the methods are available in the Online
Supplementary Appendix.

Statistical analysis
The Mann-Whitney U test was used to evaluate the differences,
at various time-points, in circulating ATG concentrations, cytokine
levels and antibody titers between patients treated with hATG or
rATG and between patients with or without SS. Statistical significance was set at 0.05 for all tests.

Results
Pharmacokinetics of rabbit and horse antithymocyte
globulins
We evaluated the pharmacokinetics of ATG in the
patients’ plasma by ELISA. To avoid the possible impact of
clinical SS on ATG concentrations in blood, we only
included patients without SS in this analysis. In both
rATG-treated (n=39) and hATG-treated (n=43) patients,
ATG reached high plasma concentrations 2 days after the
first infusion, peaking at week 1 (100.8±4.2 μg/mL and
237.6±12.7 μg/mL for rATG and hATG, respectively), and
then gradually decreased. The hATG concentration
decreased by 18%, 46%, and 74%, while the rATG concentration decreased by 3%, 18%, and 45% from peak
values when assessed at week 2, week 3, and 1 month,
respectively (Figure 1A). When patients’ serial plasma
samples were assayed by western blotting, ATG in the
plasma was detected by anti-horse IgG or anti-rabbit IgGconjugated with peroxidase. The results of the immunoblotting were consistent with those of ELISA, and a representative result is shown in Figure 1B: a weak band was
1434

detected in the plasma of a rATG-treated patient on day 1,
followed by much more intense bands, sustained until day
28. The kinetics of hATG differed: peak levels occurred on
day 4 (similar to rATG) but levels gradually decreased by
day 14 and were barely detectable on days 21 and 28.
These data indicate that the pharmacokinetics of rATG
was different from that of hATG: plasma levels of rATG
remained high for longer than those of hATG.
We next assessed whether free ATG in patients’ plasma
could bind to normal lymphocytes, using flow cytometry
to detect cell membrane-bound heterologous protein.
rATG in patients’ plasma at day 3, day 14 and 1 month
after therapy was found bound to CD3+ T cells and CD3lymphocytes obtained from healthy controls (lower panel
of Figure 1C), while hATG binding to T cells and non-T
cells was not detectable 2 weeks after the initial infusion
(upper panel of Figure 1C), consistent with a shorter halflife of hATG in the circulation and more binding of rATG
to human lymphocytes in vivo. Similarly, rATG in patients’
plasma was also shown to have more sustained binding
capacity to CD4+, CD8+ T cells, and CD19+ B cells as compared to hATG in patients’ plasma (data not shown). These
differences are likely to account for the more prolonged
lymphopenia observed with rATG than with hATG.

Effect of antithymocyte globulins on neutrophils
We compared complete blood cell counts from baseline
to 6 months in all patients treated with rATG or hATG.
hATG induced a stable increase in absolute neutrophil
counts in the first week, distinct from its effects on lymphocytes, while rATG induced a decrease in absolute neutrophil counts similar to its effect on lymphocytes in the
first 5 days after treatment. Ten days later, both hATG and
rATG resulted in similar changes in absolute neutrophil
counts, although the counts were higher in hATG-treated
patients than in rATG-treated patients at 3 and 6 months,
perhaps because of the higher response rate in the hATG
group (Figure 2A). Indeed, when stratifying based on
hematologic response, among the responding patients in
these two ATG groups, there were no differences in
absolute neutrophil counts at 3 and 6 months (Figure 2B).
In contrast to the differences in absolute neutrophil counts
and lymphocyte counts, no differences were observed in
hemoglobin and platelet levels between the two groups
(data not shown).

Effect of antithymocyte globulins on lymphocytes
Our previously published flow cytometry data showed
that rATG induced more severe and prolonged lymphopenia than did hATG, especially affecting the CD4+ T-cell
subset; absolute numbers of regulatory T cells were also
lower in rATG-treated patients, both during and after
treatment.6 In the current work, we extended flow cytometry to other immune cells. The frequencies of activated
CD4+ T cells (CD38+), double-negative (CD3+CD4-CD8-) T
cells, and B cells (CD19+) were higher in the peripheral
blood of rATG-treated patients from the first week to
months after treatment, but these effects were negated by
stronger lymphocyte depletion after rATG, and the
absolute number of these cells was not higher in rATGtreated patients (Figure 3). Double-negative T cells constitute a distinct regulatory T-cell population that may play
an immune regulatory role, but the small total number of
these cells may limit their functional effect, as we found
for (CD4+CD25highCD127low) regulatory T cells.6
haematologica | 2014; 99(9)
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Figure 1. Pharmacokinetics of rabbit ATG and horse ATG. (A) Concentrations of rATG (n=39) and hATG (n=43) detected by ELISA. ELISA plates
were coated with rabbit anti-horse IgG (Fab’2) or chicken anti-rabbit IgG to capture hATG and rATG in the plasma, respectively. The bars represent mean ± standard error (SE). (B) Western blotting for the different types of ATG in the plasma. One microliter of plasma obtained from
patients at different time points was used for western blotting. Representative data from at least three experiments with similar results are
shown. (C) Binding of rATG and hATG in patients’ plasma to lymphocytes from healthy volunteers. Representative data from at least three
experiments with similar results are shown. Cells in the plots were gated from lymphocytes based on forward and side scatter.
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Figure 2. Changes of absolute neutrophil count (ANC) in patients treated with different types of ATG. (A) Changes of ANC in all hATG (n = 60)
and rATG (n = 60)-treated patients (including responders and non-responders). (B) Changes of ANC in responder patients treated with rATG (n
= 22) or hATG (n = 41). The bars represent mean ± SE. *P<0.05; **P<0.01; ***P<0.001.
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Effect of antithymocyte globulins on cytokines
We evaluated changes in plasma cytokine levels using
magnetic multiplex assays of 27 cytokines simultaneously.
Both types of ATG induced massive, transient release of
interleukin (IL)-6, IL-8, chemokine (C-C motif) ligand
(CCL)-2, granulocyte colony-stimulating factor (G-CSF),
interferon-gamma inducible protein-10 (IP-10), IL-10
(P<0.001), IL-4, IL-13, interferon gamma (IFNγ), CCL4,
tumor necrosis factor-alpha (TNFα) (P<0.01), IL-7, IL-15,
and CCL3 (P<0.05) on day 2 of administration, likely a
direct effect of rATG and hATG (Figure 4A). There were
no differences between the two types of ATG except for
CCL4 levels (Figure 4B), which were higher in rATG-treated patients from day 7 to 21 than in hATG-treated patients
(day 7, P<0.001; days 14 and 21, P<0.01). G-CSF and CCL2 levels were higher in the rATG cohort than in the hATG
patients at day 7 (P<0.05), while eotaxin and IL-5 levels
were higher in hATG recipients than rATG recipients at
week 2 (P<0.05, data not shown). These results suggest that
some inflammatory cytokines (CCL4 and CCL2) may be
preferentially increased after rATG. No differences in plasma levels of other cytokines were observed between
rATG- and hATG-treated patients.
When comparing patients who responded and those who
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As foreign proteins, ATG elicit strong immune responses
in humans. Foreign antigens and host antibodies form circulating immune complexes that may deposit in tissues
and cause SS, usually around day 10 after initiation of ATG
therapy. Indeed, ATG administration has provided a
unique opportunity for the modern study of a historic syndrome.9 In our cohort, 15 of 60 (25%) rATG-treated
patients and 9 of 60 (15%) hATG-treated patients developed clinical SS, with typical manifestations of fever,
arthralgia, malaise, and cutaneous eruptions. Surprisingly,
we found that ATG concentrations, as measured by ELISA
(Figure 5A) and western blotting (Figure 5B), were higher
on day 1 in patients with SS than in those without the syndrome, especially in the rATG-treated group. Both rATG
and hATG concentrations decreased sharply in patients
with SS, compared to those in patients without SS, after
week 2, especially for rATG, reaching almost undetectable
levels on day 14 in patients with SS treated with rATG
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did not (Figure 4C), we found that non-responders had
higher levels of CCL2, CCL4, and IL-8 (P<0.05) before treatment, especially of CCL2, the higher levels of which persisted over time in non-responders (days 21 and 28, P<0.05).
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Figure 3. Recovery of different lymphocyte populations after hATG or
rATG treatment. CD38+
cells were gated from
CD45+CD3+CD4+CD8- T
cells; double-negative T
cells were gated from
CD45+CD3+CD4-CD8- T
cells; B cells (CD19+)
were gated from CD45+
cells. Left panel shows
frequencies and right
panel shows absolute
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populations. The bars
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**P<0.01;
***P< 0.001.
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(Figure 5B). These observations suggest that the early
appearance of rATG in the circulation on day 1 may be predictive of SS, and that rapid disappearance of rATG in the
circulation on day 14 is associated with the syndrome.
To confirm the relationship of the clearance of ATG and
antibody titers against ATG, we examined human antiATG antibody titers in the plasma of 42 patients treated
with hATG and 38 treated with rATG. When measured by
ELISA, human anti-hATG and rATG antibody titers
peaked at weeks 2-3 and then declined. All 11 rATG-treated patients who developed SS had significantly higher
antibody titers, including IgG, IgA, and IgM isotypes from
week 2 to 1 month, than those found in 29 rATG-treated
patients without SS. Among the hATG-treated patients,
only IgM antibody titers were higher in SS patients (Figure
6A). Human anti-rATG or hATG antibody titers correlated
with the occurrence of SS, the IgM subtype appearing
more specific, consistent with previous findings.9,10 In
addition, we did not find any correlation of SS with
response to ATG treatment, or with neutrophil and red
blood cell counts, but SS was associated with higher
platelet counts from week 2 to 6 months (Figure 6B).
In Luminex assays, patients with SS (whether treated
with hATG or rATG) had significantly higher plasma levels of granulocyte-monocyte colony-stimulating factor
(GM-CSF), IL-1b, IL-2, IL-17, IL-1 receptor antagonist (IL1ra), IL-12, fibroblast growth factor-b (FGFb), CCL3, and

A

hATG-IgM

IL-6 at weeks 2 and 3 than did patients without SS (Figure
7); these increased cytokines may represent a SS cytokine
signature, and this late-phase response is likely secondary
to immune complex formation. There were no significant
differences in SS-associated cytokine release between
rATG- and hATG-treated patients.

Discussion
rATG has been widely used as preconditioning for organ
transplantation and in preventing graft rejection.11 Direct
comparison of rATG and hATG in the treatment of acute
graft rejection episodes following renal transplantation
showed that rATG is more effective.12 In severe AA, the
result was the reverse. The pharmacokinetics and
immunological perturbations of both rATG and hATG
have not been studied systematically in severe AA.
In the current work, we found that rATG, functionally
able to bind human lymphocytes, remained in blood
longer than did hATG. Although long-lasting rATG in
blood could reduce the numbers of presumably pathogenic T cells, it also decreased likely non-pathogenic T cells
(especially CD4+ T cells) and neutrophils, potentially predisposing to infections and delaying evidence of hematologic recovery. It has been reported that renal transplant
recipients with persistent CD4+ T-cell lymphopenia
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induced by rATG had higher rates of mortality and morbidity, including infections and cancer.13 In our ATG-treated patients, the most prevalent complications were infections: one hATG patient and eight rATG patients went
“off study” due to recurrent life-threatening systemic
infections not adequately controlled with antimicrobials,
in the setting of progressive pancytopenia. CD4+ T cell
lymphopenia might contribute to this complication,
adding to susceptibility from the more severe and prolonged neutropenia with rATG. As we previously reported,14 Epstein-Barr viral loads were observed to be higher,
and lymphopenia was also more prolonged, following
rATG when it was administered as salvage therapy, as
compared to hATG as first-line treatment. The current
analysis directly comparing lymphocyte depletion kinetics
between types of ATG as first therapy confirms these
data, the likely mechanism being depression of both neutrophils and T cells in patients who received rATG, compared to patients who received hATG. The T-cell/B-cell
ratio has been reported to be associated with Epstein-Barr

virus-associated lymphoproliferative disorders after bone
marrow transplantation from matched unrelated donors.15
The EBMT prospective study comparing outcomes
between patients treated with rATG or hATG showed
increased infectious deaths with rATG;16 in addition, a
recent Japanese study on rATG in children also showed an
increased infection rate.17 Moreover, imbalanced lymphocyte subsets of activated CD4+ (CD38+), double-negative T
cells (CD3+CD4-CD8-), and regulatory T cells in rATGtreated patients may also affect immune system functions.
Guttmann et al. reported that the first dose of ATG
induced TNFα and IL-6 secretion in renal transplantation
patients but that subsequent doses of ATG did not have
the same effect on cytokine production.18 We found that
the ATG-induced “cytokine storm” includes not only
TNFα and IL-6 but also IL-8, CCL-2, G-CSF, IP-10, IL-10,
IL-4, IL-13, IFNγ, CCL4, IL-7, IL-15, and CCL3, and occurs
after either rATG or hATG infusion. These cytokines
appeared in the blood transiently, likely due to accelerated
activation and elimination of T-lymphocytes and other
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immune cells. The pattern of cytokine release was very
similar for rATG and hATG, except that CCL4 levels were
much higher in rATG-treated patients than in hATG-treated ones, from 1 to 3 weeks. CCL2 was also inversely correlated with hematologic response. This persistent inflammatory environment might affect the efficacy of rATG
and increase its toxicity.
SS is a historically important syndrome, first reported in
individuals who received animal antisera, and, as we had
observed previously, it occurred in some of our patients
after ATG. The pathophysiology of SS is understood to be
secondary to host antibody responses to foreign proteins
followed by formation and then deposition of immune
complexes in tissues (skin, joints, and other organs). Both
the dose and regimen of antigen administration and the
quality of the immune response would be factors in the
production of SS; additionally, certain antigens might
stimulate specific patterns of host immune response and
cytokine release. The total dose of hATG is much higher
(almost 10-fold) than that of rATG. However, rATG is
detectable in blood for much longer and at apparently
equivalent or higher amounts, as determined by immuneblotting. Within the group of patients who received
rATG, ATG concentrations on day 1 were higher than in
non-SS patients; we did not see such a difference in hATGtreated patients. Concentrations of both types of ATG
decreased at about week 2 when SS occurred, with clearance being associated with the appearance of antibodies
against ATG, especially IgM. It is remarkable that, despite
marked differences in the amount of antigen infused
between hATG and rATG, and presumed differences also
in the immune response to horse and rabbit proteins, the
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